Revvity Announces Financial Results for the First Quarter of 2025

Original from: Revvity

· Revenue of $665 million; 2% reported growth; 4% organic growth

· GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01

· Reaffirms full year 2025 organic growth and adjusted EPS guidance

Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025.

The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continuing operations was 10.9% as a percentage of revenue, as compared to 6.8% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.01, as compared to $0.98 in the same period a year ago. Adjusted operating income was $170 million, as compared to $166 million for the same period a year ago. Adjusted operating profit margin was 25.6% as a percentage of revenue, as compared to 25.5% in the same period a year ago.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

“Revvity navigated a dynamic environment and delivered strong first quarter results,” said Prahlad Singh, president and chief executive officer of Revvity. “Our strong execution combined with the uniqueness of our businesses drove our revenue, earnings and cash flow to each exceed our expectations in the quarter. Our first quarter performance positions us well for the remainder of the year as we continue to adapt to an evolving macroeconomic backdrop.”

Financial Overview by Reporting Segment

Life Sciences

First quarter 2025 revenue was $340 million, as compared to $337 million in the same period a year ago. Revenue increased 1% and organic revenue increased 2% as compared to the same period a year ago.

First quarter 2025 adjusted operating income was $106 million, as compared to $101 million in the same period a year ago. Adjusted operating profit margin was 31.1% as a percentage of revenue, as compared to 30.0% in the same period a year ago.

Diagnostics

First quarter 2025 revenue was $324 million, as compared to $313 million in the same period a year ago. Revenue increased 3% and organic revenue increased 5% as compared to the same period a year ago.

First quarter 2025 adjusted operating income was $74 million, as compared to $76 million in the same period a year ago. Adjusted operating profit margin was 22.8% as a percentage of revenue, as compared to 24.3% in the same period a year ago.

Full Year 2025 Guidance

For the full year 2025, the Company is raising its revenue guidance to a range of $2.83-$2.87 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 3-5%. Additionally, the Company is reaffirming its adjusted EPS guidance of $4.90-$5.00.

Guidance for the full year 2025 for adjusted EPS and organic growth is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Source: Revvity Announces Financial Results for the First Quarter of 2025